Table 3.
Performance of European and US First-Tier Enzyme-Linked Immunosorbent Assays
| No. Positive (%) |
|||||
|---|---|---|---|---|---|
| European WCS IgM | European WCS/rVlsE IgG | European IgM or IgG | US WCS IgM/IgG | US C6 Peptide | |
| Patients with Lyme borreliosis acquired in Europe (n = 64) | 39 (61) | 55 (86) | 58 (91) | 55 (86) [0.58] | 56 (88) [.78] |
| Erythema migrans (n = 20) | 8 (40) | 13 (65) | 15 (75) | 14 (70) [1.00] | 14 (70) [1.00] |
| Lyme neuroborreliosis (n = 15) | 12 (80) | 13 (87) | 14 (93) | 13 (87) [1.00] | 13 (87) [1.00] |
| Lyme arthritis (n = 15) | 9 (60) | 15 (100) | 15 (100) | 14 (93) [1.00] | 15 (100) [1.00] |
| Acrodermatitis chronica atrophicans (n = 14) | 10 (71) | 14 (100) | 14 (100) | 14 (100) [1.00] | 14 (100) [1.00] |
| Healthy control subjects from nonendemic area (n = 100) | 2 (2) | 2 (2) | 4 (4) | 3 (3) [1.00] | 0 (0) [0.12] |
Bracketed numbers represent the P values for the comparison with combined results obtained using European IgM and IgG enzyme-linked immunosorbent assays.
Abbreviations: IgG, immunoglobulin G; IgM, immunoglobulin M; rVlsE, recombinant Vmp-like sequence, expressed; WCS, whole-cell sonicate.